CBD in Autoimmune Hepatitis (Phase 2a)

Introduction and clinical context

The study CBD in Autoimmune Hepatitis (Phase 2a) (ClinicalTrials.gov · em andamento) is part of the scientific research on the use of cannabinoids in other conditions.

This section gathers research on the use of cannabinoids in various conditions — from autoimmune and dermatological diseases to pharmacokinetics and drug-interaction studies. These are, in general, exploratory studies or ongoing registrations that broaden the research map on medical cannabis. Each case has its own level of evidence, and none replaces an individualized clinical assessment.

Understanding what science shows about the use of cannabinoids in other conditions helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study is registered on ClinicalTrials.gov and is ongoing. Phase 2a study of the safety and efficacy of cannabidiol in autoimmune hepatitis. As it is ongoing, there are no final published results yet. Following ongoing studies is important to anticipate the next evidence on the topic.

Mechanism of action and safety

The rationale varies by condition: cannabinoids act on CB1/CB2 receptors and related targets, with anti-inflammatory, analgesic or immunomodulatory effects depending on the case. In pharmacokinetic studies, researchers investigate how the body absorbs and metabolizes the compound — relevant for interactions, especially via the cytochrome P450 pathway. Safety depends on the formulation and dose, with common effects such as drowsiness and dizziness. Since many are exploratory studies, the conclusions are preliminary and use should always be guided by a healthcare professional.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (ClinicalTrials.gov · em andamento). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Are these uses already approved?

They are, in general, exploratory or ongoing studies; the level of evidence varies case by case.

What is pharmacokinetics?

It is the study of how the body absorbs, distributes, metabolizes and eliminates a substance.